The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is one of the most common causes of chronic neurological disability beginning in early to middle adult life. Multiple sclerosis is idiopathic in nature, yet increasing correlative evidence supports a strong association between one’s genetic predisposition, the environment and the immune system. Symptoms of multiple sclerosis have primarily been shown to result from a disruption in the integrity of myelinated tracts within the white matter of the central nervous system. However, recent research has also highlighted the hitherto underappreciated involvement of gray matter in multiple sclerosis disease pathophysiology, which may be especially relevant when considering the accumulation of irreversible damage and progressive disability. This review aims at providing a comprehensive overview of the interplay between inflammation, glial/neuronal damage and regeneration throughout the course of multiple sclerosis via the analysis of both white and gray matter lesional pathology. Further, we describe the common pathological mechanisms underlying both relapsing and progressive forms of multiple sclerosis, and analyze how current (as well as future) treatments may interact and/or interfere with its pathology. Understanding the putative mechanisms that drive disease pathogenesis will be key in helping to develop effective therapeutic strategies to prevent, mitigate, and treat the diverse morbidities associated with multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“…and reactive oxygen and nitrogen species) and an anti-inflammatory (alternatively-activated) M2-like state (associated with an increase in angiogenic capacity, and the secretion of anti-inflammatory cytokines, growth and neurotrophic factors) (Biswas and Mantovani, 2010; Miron and Franklin, 2014).”
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Cognitive impairment in multiple sclerosis
Chiaravalloti, N. D., & DeLuca, J. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70259-x · Cited by 2,088
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 2×
“Therefore, the different processes that drive demyelination at the level of white matter (WM), as well as damage of the gray matter (GM), should be interpreted as major determinants of disease heterogeneity in MS patients (Lassmann et al., 2012; Trapp and Nave, 2008).”
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 1×
“A unifying hypothesis suggests that distant WM inflammation can induce a retrograde neurodegeneration that leads to microglia activation within the cortex (Lassmann, 2012; Perry et al., 2010).”
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 6×
“The extent of GM involvement in MS has since been confirmed using myelin specific protein immunohistochemistry, and today the critical importance of GM pathology in MS is well accepted (Bo et al., 2003a; Peterson et al., 2001).”
InfluentialBarkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251 · cited 2×
“, 2010) and its role in the diagnosis of clinical MS is paramount (Barkhof et al., 1997; Polman et al., 2011).”
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205 · cited 1×
“Alemtuzumab has been recently licensed for the treatment of RR MS by the FDA and when compared to IFN-b 1a, has shown great efficacy in reducing relapse rates, disability and MRI activity (Tuohy et al., 2015; Cohen et al., 2012; Coles et al., 2012; Investigators et al., 2008).”
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198 · cited 1×
“Alemtuzumab has been recently licensed for the treatment of RR MS by the FDA and when compared to IFN-b 1a, has shown great efficacy in reducing relapse rates, disability and MRI activity (Tuohy et al., 2015; Cohen et al., 2012; Coles et al., 2012; Investigators et al., 2008).”
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103 · cited 6×
“Despite the validity of the described classification system for patients with chronic MS, recent research on brain biopsies obtained from patients with early MS have revealed that GM lesions do in fact show profound lymphocytic infiltration, increased BBB damage and meningeal inflammation at their very onset (Lucchine…”
InfluentialProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033 · cited 2×
“Therefore, the different processes that drive demyelination at the level of white matter (WM), as well as damage of the gray matter (GM), should be interpreted as major determinants of disease heterogeneity in MS patients (Lassmann et al., 2012; Trapp and Nave, 2008).”
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 2×
“…on patients with progressive MS have revealed that the density of OPCs and premyelinating oligodendrocytes is not decreased in cortical lesions (Chang et al., 2002), and this is likely due to a more permissive microenvironment for OPCs within the cortex (e.g. less extracellular matrix…”
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862 · cited 1×
“…cytokines [e.g. tumor necrosis factor (TNF)-a and IFN-g], reactive oxygen species, and proteolytic/lipolytic enzymes are also released by activated microglia/macrophages, and further amplify the initial activation of T cells (McMahon et al., 2005; Greter et al., 2005; Heppner et al., 2005).”
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766 · cited 1×
“The first classification of GM lesions, identified seven types which depended on their relationship to the cortical veins (Kidd et al., 1999).”
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757 · cited 4×
“The extent of GM involvement in MS has since been confirmed using myelin specific protein immunohistochemistry, and today the critical importance of GM pathology in MS is well accepted (Bo et al., 2003a; Peterson et al., 2001).”
InfluentialExperimental autoimmune encephalomyelitis repressed by microglial paralysis
Heppner, F. L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., Waisman, A., Rülicke, T., Prinz, M., Priller, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1177 · Cited by 732 · cited 1×
“…cytokines [e.g. tumor necrosis factor (TNF)-a and IFN-g], reactive oxygen species, and proteolytic/lipolytic enzymes are also released by activated microglia/macrophages, and further amplify the initial activation of T cells (McMahon et al., 2005; Greter et al., 2005; Heppner et al., 2005).”
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694 · cited 2×
“…cytokines [e.g. tumor necrosis factor (TNF)-a and IFN-g], reactive oxygen species, and proteolytic/lipolytic enzymes are also released by activated microglia/macrophages, and further amplify the initial activation of T cells (McMahon et al., 2005; Greter et al., 2005; Heppner et al., 2005).”
Capture, crawl, cross: the T cell code to breach the blood–brain barriers
Engelhardt, B., & Ransohoff, R. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.004 · Cited by 686 · cited 4×
“T cells then cross the endothelial layer via diapedesis (Engelhardt and Ransohoff, 2012), the endothelial basement membrane via a6b1 integrindependent activation (Sixt et al.”
InfluentialMyelination and the trophic support of long axons
Nave, K.-A. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2797 · Cited by 648
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621 · cited 1×
“This imbalance between increased energy demand and decreased energy supply has been termed virtual hypoxia and eventually leads to degeneration of the axon in the WM (Lassmann, 2003; Trapp and Stys, 2009).”
Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 2×
“, 2013) and hyaluronan (Back et al., 2005) are all inhibitory for remyelination.”
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Bjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573 · cited 1×
“While this process may remain clinically silent for many years, irreversible neurological disability ensues as compensatory CNS resources are exhausted and neurodegenerative mechanisms triggered (Bjartmar et al., 2003).”
Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., Opdenakker, G., & Sorokin, L. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051342 · Cited by 559
Retinoid X receptor gamma signaling accelerates CNS remyelination
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, C., Evercooren, A. B.-V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2702 · Cited by 547
A regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
Iron and neurodegeneration in the multiple sclerosis brain
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Brück, W., & Lassmann, H. (2013) · Annals of Neurology · doi:10.1002/ana.23974 · Cited by 519
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration
Bø, L., Vedeler, C. A., Nyland, H., Trapp, B. D., & Mørk, S. J. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms917oa · Cited by 478 · cited 4×
“The extent of GM involvement in MS has since been confirmed using myelin specific protein immunohistochemistry, and today the critical importance of GM pathology in MS is well accepted (Bo et al., 2003a; Peterson et al., 2001).”
InfluentialA quantitative analysis of oligodendrocytes in multiple sclerosis lesions
Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., & Lassmann, H. (1999) · Brain · doi:10.1093/brain/122.12.2279 · Cited by 464
Remyelination protects axons from demyelination-associated axon degeneration
Irvine, K. A., & Blakemore, W. F. (2008) · Brain · doi:10.1093/brain/awn080 · Cited by 420 · cited 3×
“Following demyelination, Na+ channels that are normally located at the nodes of Ranvier become diffusely distributed along the axolemma.”
bHLH Transcription Factor Olig1 Is Required to Repair Demyelinated Lesions in the CNS
Arnett, H. A., Fancy, S. P. J., Alberta, J. A., Zhao, C., Plant, S. R., Kaing, S., Raine, C. S., Rowitch, D. H., Franklin, R. J. M., & Stiles, C. D. (2004) · Science · doi:10.1126/science.1103709 · Cited by 416
Takahashi, K., Prinz, M., Stagi, M., Chechneva, O., & Neumann, H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040124 · Cited by 414 · cited 1×
“The presence of microglia/macrophages in every step of the evolving GM lesion suggests a role for mononuclear cells in clearing the environment of growth inhibitory molecules (Piccio et al., 2007; Takahashi et al., 2007).”
Mitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406 · cited 3×
“Excessive axoplasmic Ca accumulation causes a vicious cycle of impaired mitochondrial function, reduced energy production and compromised axonal transport that further propagates damage (Mahad et al., 2008).”
InfluentialMeningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Choi, S. R., Howell, O. W., Carassiti, D., Magliozzi, R., Gveric, D., Muraro, P. A., Nicholas, R., Roncaroli, F., & Reynolds, R. (2012) · Brain · doi:10.1093/brain/aws189 · Cited by 386
Disease-specific molecular events in cortical multiple sclerosis lesions
Fischer, M. T., Wimmer, I., Höftberger, R., Gerlach, S., Haider, L., Zrzavy, T., Hametner, S., Mahad, D., Binder, C. J., Krumbholz, M., et al. (2013) · Brain · doi:10.1093/brain/awt110 · Cited by 311 · cited 2×
“Consistently, a recent gene expression study on actively demyelinating subpial cortical lesions supported the idea that oxidative injury may be one of the major driving forces of cortical demyelination (Fischer et al., 2013).”
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
Fazekas, F., Barkhof, F., Filippi, M., Grossman, R. I., Li, D. K. B., McDonald, W. I., McFarland, H. F., Paty, D. W., Simon, J. H., Wolinsky, J. S., et al. (1999) · Neurology · doi:10.1212/wnl.53.3.448 · Cited by 287 · cited 2×
“Both early neuropathological reports and contemporary MRI findings have clearly demonstrated that WM lesions have a tendency to involve the optic nerve and a propensity to locate to the periventricular WM, juxtacortical border and to the cerebellum/brainstem of MS patients (Charcot, 1848; Fazekas et al., 1999).”
Blockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitis
Piccio, L., Buonsanti, C., Mariani, M., Cella, M., Gilfillan, S., Cross, A. H., Colonna, M., & Panina‐Bordignon, P. (2007) · European Journal of Immunology · doi:10.1002/eji.200636837 · Cited by 284 · cited 1×
“The presence of microglia/macrophages in every step of the evolving GM lesion suggests a role for mononuclear cells in clearing the environment of growth inhibitory molecules (Piccio et al., 2007; Takahashi et al., 2007).”
MRI criteria for MS in patients with clinically isolated syndromes
Montalban, X., Tintoré, M., Swanton, J., Barkhof, F., Fazekas, F., Filippi, M., Frederiksen, J., Kappos, L., Palace, J., Polman, C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cec45c · Cited by 252 · cited 2×
“MRI is currently the most sensitive technique for detecting WM lesions in vivo (Montalban et al., 2010) and its role in the diagnosis of clinical MS is paramount (Barkhof et al.”
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Teratomas from pluripotent stem cells: A clinical hurdle
Fong, C., Gauthaman, K., & Bongso, A. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22775 · Cited by 222
The benefits and detriments of macrophages/microglia in models of multiple sclerosis
Rawji, K. S., & Yong, V. W. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/948976 · Cited by 217 · cited 2×
“brain-derived neurotrophic factor, nerve growth factor, neurotrophin-3 and oncomodulin) and indirectly stimulating (via IL-1b) local CNTF production (Martino, 2004; Rawji and Yong, 2013).”
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216 · cited 2×
“…of OPCs and premyelinating oligodendrocytes is not decreased in cortical lesions (Chang et al., 2002), and this is likely due to a more permissive microenvironment for OPCs within the cortex (e.g. less extracellular matrix molecules and less astrogliosis), as later described (Chang et al., 2012).”
Human neural stem cells ameliorate autoimmune encephalomyelitis in non‐human primates
Pluchino, S., Gritti, A., Blezer, E., Amadio, S., Brambilla, E., Borsellino, G., Cossetti, C., Del Carro, U., Comi, G., 't Hart, B., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21745 · Cited by 208
Self-citationBrink, B. P., Veerhuis, R., Breij, E. C. W., van der Valk, P., Dijkstra, C. D., & Bö, L. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.147 · Cited by 191
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability
Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P. M., Reynolds, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635645 · Cited by 176 · cited 2×
“activation by PK11195 positron emission tomography (PET) binding has revealed extensive regional activation of microglia in the MS cortex of both RR MS (40% of cases) and SP MS patients (75% of cases) (Politis et al., 2012).”
Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis
Adams, C. W. M., Poston, R. N., & Buk, S. J. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90144-5 · Cited by 163
The translational biology of remyelination: past, present, and future
Franklin, R. J. M., & Gallo, V. (2014) · Glia · doi:10.1002/glia.22622 · Cited by 162
Ascl1/Mash1 Promotes Brain Oligodendrogenesis during Myelination and Remyelination
Nakatani, H., Martin, E., Hassani, H., Clavairoly, A., Maire, C. L., Viadieu, A., Kerninon, C., Delmasure, A., Frah, M., Weber, M., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0805-13.2013 · Cited by 158 · cited 2×
“Similarly, Ascl-1 expression is increased at the active border of MS lesions, and guides OPC differentiation (Nakatani et al., 2013).”
Murtie, J. C., Zhou, Y.-X., Le, T. Q., Vana, A. C., & Armstrong, R. C. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.006 · Cited by 157
Preactive lesions in multiple sclerosis
van der Valk, P., & Amor, S. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832b4c76 · Cited by 156 · cited 2×
“The observation of clusters of activated microglia (HLA-DR+, CD68+ and CD45high) within the CNS of MS patients in the absence of BBB derangement, demyelination, axonal loss, and T cell activation, has challenged previous theories on MS pathogenesis (Van der Valk and Amor, 2009).”
Macrophages in Multiple Sclerosis
Brück, W., Sommermeier, N., Bergmann, M., Zettl, U., Goebel, H. H., Kretzschmar, H. A., & Lassmann, H. (1996) · Immunobiology · doi:10.1016/s0171-2985(96)80024-6 · Cited by 139 · cited 1×
“To overcome this limitation, a new categorization of active WM lesions was put forth to combine the state of macrophage activation and concomitant myelin degradation (Bruck et al., 1996).”
Molecular Mimicry in Multiple Sclerosis
Libbey, J. E., McCoy, L. L., & Fujinami, R. S. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)79006-2 · Cited by 102 · cited 2×
“Two major mechanisms have come to prominence in an effort to identify the most likely triggers of MS and are as follows: molecular mimicry between self-antigens and infectious agents and bystander activation of autoreactive immune T cells (Libbey et al., 2007; Sospedra and Martin, 2005).”
Cited by
Blood-brain barrier dysfunction and recovery after ischemic stroke
Jiang, X., Andjelkovic, A. V., Zhu, L., Yang, T., Bennett, M. V. L., Chen, J., Keep, R. F., & Shi, Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.001 · Cited by 936
The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis
Mandolesi, G., Gentile, A., Musella, A., Fresegna, D., De Vito, F., Bullitta, S., Sepman, H., Marfia, G. A., & Centonze, D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.222 · Cited by 286
Peruzzotti-Jametti, L., Bernstock, J. D., Vicario, N., Costa, A. S. H., Kwok, C. K., Leonardi, T., Booty, L. M., Bicci, I., Balzarotti, B., Volpe, G., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.01.020 · Cited by 285
Self-citationInflammatory mediators in human epilepsy: A systematic review and meta-analysis
de Vries, E. E., van den Munckhof, B., Braun, K. P. J., van Royen-Kerkhof, A., de Jager, W., & Jansen, F. E. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.007 · Cited by 269
Metadata
- Authors
- Mallucci, G., Peruzzotti-Jametti, L., Bernstock, J. D., & Pluchino, S.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 127-128
- Pages
- 1-22
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W1994878371
- Cited by
- 145
- References
- 68
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.